These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20889657)

  • 1. Does antidepressant step therapy fuel the law of unintended consequences?
    Greden JF
    Am J Psychiatry; 2010 Oct; 167(10):1148-51. PubMed ID: 20889657
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures.
    Mark TL; Gibson TM; McGuigan K; Chu BC
    Am J Psychiatry; 2010 Oct; 167(10):1202-9. PubMed ID: 20713497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
    Schultz J; Joish V
    Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of pharmacotherapy for major depressive disorder.
    Dupuy JM; Ostacher MJ; Huffman J; Perlis RH; Nierenberg AA
    Int J Neuropsychopharmacol; 2011 Nov; 14(10):1417-31. PubMed ID: 21349226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
    Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
    BMC Health Serv Res; 2013 May; 13():173. PubMed ID: 23663281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in generic sertraline for children: real or artefact from cost containing to clinical quality of generics use.
    Maurizio B; Silvia M; Antonio C
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1083-5. PubMed ID: 17089109
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost sharing and branded antidepressant initiation among patients treated with generics.
    Buxbaum JD; Chernew ME; Bonafede M; Vlahiotis A; Walter D; Mucha L; Fendrick AM
    Am J Manag Care; 2018 Apr; 24(4):180-186. PubMed ID: 29668208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Employers push to manage prescription drug costs.
    Frieden J
    Bus Health; 1992 May; 10(6):43-6, 48, 50. PubMed ID: 10119119
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis.
    François C; Despiégel N; Maman K; Saragoussi D; Auquier P
    J Med Econ; 2010 Mar; 13(1):99-109. PubMed ID: 20078336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis.
    McCombs JS; Ahn J; Tencer T; Shi L
    J Affect Disord; 2007 Jan; 97(1-3):171-9. PubMed ID: 16860396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents.
    Ferrand Y; Kelton CM; Guo JJ; Levy MS; Yu Y
    Res Social Adm Pharm; 2011 Mar; 7(1):64-80. PubMed ID: 21397882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs associated with antidepressant use in depression and anxiety in community-living older adults.
    Vasiliadis HM; Latimer E; Dionne PA; Préville M
    Can J Psychiatry; 2013 Apr; 58(4):201-9. PubMed ID: 23547643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cheap and cheerful.
    Munro R
    Nurs Times; 2000 Jan 20-26; 96(3):16. PubMed ID: 11961788
    [No Abstract]   [Full Text] [Related]  

  • 18. Major depression.
    Terry CM; Thomas S; Cave DG
    Manag Care Interface; 1998 Nov; 11(11):58-60. PubMed ID: 10187417
    [No Abstract]   [Full Text] [Related]  

  • 19. The rising utilization and costs of prescription drugs.
    PHC4 FYI; 2004; (26):1-2. PubMed ID: 15344277
    [No Abstract]   [Full Text] [Related]  

  • 20. The health value and cost of care for major depression.
    Watkins KE; Burnam MA; Orlando M; Escarce JJ; Huskamp HA; Goldman HH
    Value Health; 2009; 12(1):65-72. PubMed ID: 19911440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.